Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing
STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN)
Applied DNA Sciences, Inc. (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week:
3rd Annual mRNA Process Development & Manufacturing Summit
Members of Applied DNA’s Biotherapeutics Sales and Business Development teams (collectively ‘LineaRx,’ a majority-owned Applied DNA company) will attend the 3rd Annual mRNA Process Development & Manufacturing Summit taking place September 17-19, 2024. LineaRx will present its Linea™ IVT platform – a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) – as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination.
Applied DNA Sciences, Inc. is making waves in the world of mRNA manufacturing with its cutting-edge Linea™ IVT platform. By partnering with mRNA CDMO Kudo Bio, they are set to demonstrate the capabilities of their platform at the upcoming 3rd Annual mRNA Process Development & Manufacturing Summit in Boston. This technology has the potential to revolutionize the way mRNA is produced, offering a faster and more efficient process with reduced contamination.
The Linea™ IVT platform is a game-changer for the industry, as it allows mRNA producers to streamline their workflows and improve the quality of their products. By utilizing enzymatically produced DNA templates and next-generation RNA polymerases, manufacturers can expect better results in a shorter amount of time. This technology has the potential to make a significant impact on the field of mRNA therapeutics, paving the way for advancements in healthcare and genetic research.
How will this affect me?
If you are involved in the biopharmaceutical industry or have an interest in mRNA technology, the advancement of the Linea™ IVT platform by Applied DNA Sciences, Inc. could directly impact you. This breakthrough technology has the potential to improve the efficiency and quality of mRNA manufacturing, leading to accelerated development of mRNA-based therapeutics and vaccines.
How will this affect the world?
The development of the Linea™ IVT platform by Applied DNA Sciences, Inc. has the potential to have a far-reaching impact on the world. By enabling faster and more efficient mRNA manufacturing, this technology could lead to the rapid production of vaccines and treatments for a wide range of diseases. This could revolutionize the field of biopharmaceuticals and have a positive impact on global health outcomes.
Conclusion
Applied DNA Sciences, Inc.’s partnership with mRNA CDMO Kudo Bio and the development of the Linea™ IVT platform represents a significant advancement in mRNA manufacturing technology. This innovation has the potential to revolutionize the field of biopharmaceuticals, offering faster and more efficient production methods with improved quality control. As these technologies continue to evolve, we can expect to see exciting developments in mRNA-based therapeutics and vaccines that have the potential to benefit individuals and communities worldwide.
